FDA Strengthens Fracture Warning for Canagliflozin FDA Strengthens Fracture Warning for Canagliflozin
New clinical trial data for canagliflozin confirmed previously noted risk about fractures and reduced bone mineral density in the hip and spine, prompting the FDA to revise the product label. News Alerts
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Canagliflozin | Clinical Trials | Diabetes | Endocrinology | Invokana | Orthopaedics | Warnings